Passage BIO, Inc.·3

Feb 27, 8:04 PM ET

Frazier Life Sciences IX, L.P. 3

3 · Passage BIO, Inc. · Filed Feb 27, 2020

Insider Transaction Report

Form 3
Period: 2020-02-27
Holdings
  • Series A-1 Preferred Stock

    Common Stock (2,977,242 underlying)
  • Series A-2 Preferred Stock

    Common Stock (1,049,175 underlying)
  • Series B Preferred Stock

    Common Stock (432,802 underlying)
Footnotes (4)
  • [F1]Each share of the issuer's Series A-1 Preferred Stock will automatically convert into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering ("IPO") and has no expiration date.
  • [F2]The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The reporting person and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
  • [F3]Each share of the issuer's Series A-2 Preferred Stock will automatically convert into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.
  • [F4]Each share of the issuer's Series B Preferred Stock will automatically convert into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.

Documents

1 file
  • 3
    doc3.xmlPrimary

    FORM 3 SUBMISSION